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Disseminated cutaneous leishmaniasis and HIV
dual-infection is seldom reported. Leishmaniasis
and HIV co-infection may intensify the immune
defect and is the chief reason for atypical
presentation and widespread progression of
cutaneous leishmaniasis and its defiance to
conventional therapy. Here we report a 38-year-
old HIV-positive lady who presented with a 6-month
history of a progressive papule and nodular
eruptions of leishmaniasis on face, trunk and
extremities that was recalcitrant to treatment.
Co-infection, Diffuse cutaneous
leishmaniasis, HIV infection.
A 33 years old woman presented with a 10 months
history of asymptomatic skin lesions on the face
trunks and limbs. The lesions started on the face
and progressively spread to involve the trunk. She
was diagnosed with HIV and had been on
antiretroviral therapy (nevirapine, stavudine and
lamivudine) for about 7 months.
Introduction
Case report
Human Leishmaniasis is usually classified as
visceral, cutaneous and muco-cutaneous. Human
immunodeficiency virus (HIV) co-infection with
cutaneous leishmaniasis (CL) may be associated
with unusually severe presentations, higher rates
of recurrence and re-infection and lower cure rates
with established treatments. Disseminated
(diffuse) leishmaniasis in HIV-positive patients is
clinically characterized by multiple (>200), atypical,
widespread infiltrations of skin lesions.
1
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Physical examination showed multiple, bilateral,
asymmetrical, asymptomatic papulonodular
lesions on face (Fig1), trunk, and extremities.
Infiltrations of nasal mucosa were also found.
There was no history of pain and pruritus, and
there were no signs of ulceration and scarring.
T h e r e w a s n o l y m p h a d e n o p a t hy a n d
hepatosplenomegaly.
Laboratory investigations revealed a mild
anaemia, HB 9.5g/dl. Liver function tests, urea,
electrolytes and creatinine were all within normal
limits. CD-4 T cell count was low (30 cells/mm 3).
Ultrasonography of abdomen was normal.
Giemsa staining of scrapped materials from
cutaneous lesions showed presence of 2-3 microns
blue Leishman bodies. Histology of a punch biopsy
specimen showed a dermis with macrophages
containing great numbers of amastigotes with few
lymphocytes or plasma cells (Fig3a&b). The
patient was placed on fluconazole 200mg daily.
Antiretroviral therapy was continued. Two month
after commencement of therapy the papules and
nodules became ulcerated and more widespread
despite compliance with medication (fig 2).





Leishmania species can cause a wide spectrum of
cutaneous lesions in HIV-positive patients, the
clinical variants of leishmaniasis and clinical status
are largely determined by parasite species and
host cell mediated immunity (CMI) response.
Dissemination of lesions is determined by host
immunogenic status. The species involved in
diffuse (CL) lesions are
, and
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Fig. 1 papulonodular lesions at presentation Fig. 2-ulcerated and crusted nodule second visit
Fig. 3a huge numbers of amastigotes in  histiocytes
in dermal and subcutaneous tissue.X 40
Figure 3b Huge numbers of amastigotes in
histiocytes in X 100
Leishmaniasis and HIV co-infection may augment
the immune defect by producing cumulative
deficiency of the cell mediated immunity and
increase disease severity and morbidity. HIV-
infected patients quite often have an atypical and
severe clinical presentation of CL in terms of
number (>200), sites and types of lesions
(papulonodular).
Although CL in visceral leishmaniasis has been
reported more commonly with HIV infection,
diffuse CL in the absence of visceral involvement
has been reported as a first manifestation leading to
the diagnosis of HIV infection.
3,4
4,5
Disseminated cutaneous leishmaniasis usually
begins with an initial primary lesion and then
disseminates to involve other areas of the skin.
The lesions are non ulcerative nodules full of
parasites, which are often scattered over the
limbs, buttocks and face. The differentials of this
type of lesions include lepromatous leprosy, lupus
vulgar is , and deep fungal infect ions .
High level of clinical suspicion and tissue smears
with Giemsa are needed to make a diagnosis.
Findings in biopsy lesions in diffuse CL and HIV co-
infected patients are variable and can depend on
immune status of the patients.
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In most cases, a large and even huge numbers of
amastigotes in histiocytes can be seen in dermal
and subcutaneous tissue.
Our case had failed to respond to the chosen
medication, this is not surprising since diffuse
forms of leishmaniasis were known many years ago
7
to be refractory to anti-leishmanial treatment.
Although meglumine antimoniate , pentamidine
are considered as first-line treatments in
cutaneous leishmaniasis without HIV co-
infection, we were cautious not to use such drugs
on our patient for safety reasons.
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